Patents by Inventor Roger Sunahara
Roger Sunahara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11590089Abstract: Aspects of the present disclosure include conformationally restricted analogs of catecholamine type compounds (e.g., isoprenaline, adrenaline, noradrenaline) which activate ?2AR with high selectivity over ?1AR. The subject beta-2 selective adrenergic receptor agonist compounds may serve as bronchiodilators and find use in the treatment of a variety of bronchoconstrictive diseases and conditions. Also provided are compositions and methods for treating preterm labor. A method of treating acute asthma including administration of a subject compound to a subject in need thereof is provided. The subject method can provide for reduced undesirable side effects associated with non-selective ?-adrenergic receptor agonism, such as inotropic and chronotropic effects that leads to elevated blood pressure. The compounds can also be used to prevent or treat heart failure. Kits and compositions for practicing the subject methods are also provided.Type: GrantFiled: November 30, 2018Date of Patent: February 28, 2023Assignees: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, FRIEDRICH-ALEXANDER-UNIVERSITÄT ERLANGEN-NÜRNBERGInventors: Roger Sunahara, Harald Huebner, Jeremy Shonberg, Anne Stößel, Markus Stanek, Dorothée Möller, Mary Joyce Clark, Brian K. Kobilka, Peter Gmeiner, Luis Maul
-
Patent number: 11052044Abstract: Described herein, inter alia, are compositions and methods useful for the reconstitution of membrane proteins.Type: GrantFiled: March 1, 2018Date of Patent: July 6, 2021Assignee: The Regents of the University of CaliforniaInventors: Roberto Javier Brea Fernandez, Christian Cole, Neal K. Devaraj, Brent Lyda, Roger Sunahara
-
Publication number: 20200360304Abstract: Aspects of the present disclosure include conformationally restricted analogs of catecholamine type compounds (e.g., isoprenaline, adrenaline, noradrenaline) which activate ?2AR with high selectivity over ?1AR. The subject beta-2 selective adrenergic receptor agonist compounds may serve as bronchiodilators and find use in the treatment of a variety of bronchoconstrictive diseases and conditions. Also provided are compositions and methods for treating preterm labor. A method of treating acute asthma including administration of a subject compound to a subject in need thereof is provided. The subject method can provide for reduced undesirable side effects associated with non-selective ?-adrenergic receptor agonism, such as inotropic and chronotropic effects that leads to elevated blood pressure. The compounds can also be used to prevent or treat heart failure. Kits and compositions for practicing the subject methods are also provided.Type: ApplicationFiled: November 30, 2018Publication date: November 19, 2020Inventors: Roger SUNAHARA, Harald HUEBNER, Jeremy SHONBERG, Anne STÖßEL, Markus STANEK, Dorothée MÖLLER, Mary Joyce CLARK, Brian K. KOBILKA, Peter GMEINER, Luis MAUL
-
Publication number: 20200308168Abstract: The present invention relates to fluorophenyl substituted muscarinic receptor ligands with selectivity for M3 over M2 and to the use of these compounds in the treatment of various diseases such as asthma, chronic obstructive pulmonary disease (COPD), bronchopulmonary dysplasia (BPD) and urinary incontinence.Type: ApplicationFiled: December 3, 2018Publication date: October 1, 2020Applicants: Friedrich-Alexander-Universität Erlangen-Nürnberg, The Board of Trustees of the Leland Stanford Junior University, The Regents of the University of CaliforniaInventors: Ashutosh BANERJEE, Amelie BARTUSCHAT, Katrin EITEL, Peter GMEINER, Markus HEINRICH, Josefa HOFMANN, Harald HÜBNER, Hannelore RAMPP, Benjamin SCHAAKE, Brian KOBILKA, Roger SUNAHARA, Mary Joyce CLARK, Inbar FISH, Brian SHOICHET
-
Publication number: 20200022915Abstract: Described herein, inter alia, are compositions and methods useful for the reconstitution of membrane proteins.Type: ApplicationFiled: March 1, 2018Publication date: January 23, 2020Inventors: Roberto Javier Brea Fernandez, Christian Cole, Neal K. Devaraj, Brent Lyda, Roger Sunahara
-
Publication number: 20160160195Abstract: Embodiments of the invention disclosed herein generally relate to anti-cocaine therapeutics. Specifically, some embodiments of the invention relate to highly efficient, thermostable, and long-lasting cocaine esterase (CocE) mutants that can protect against the toxic and reinforcing effects of cocaine in subjects. Provided herein are mutant CocE polypeptides displaying thermostable esterase activity. Also provided are methods of treating cocaine-induced conditions in a subject in need via administration of mutant CocE as well as methods for high-throughput screening of candidate esterase polypeptides.Type: ApplicationFiled: November 30, 2015Publication date: June 9, 2016Applicants: The Trustees of Columbia University in the City of New York, The Regents of the University of Michigan, The University of Kentucky Research FoundationInventors: Donald Landry, Chang-Guo Zhan, James H. Woods, Roger Sunahara, Diwahar L. Narasimhan, Joanne MacDonald, Victor Yang, Mei-Chuan Holden Ko, Shi-Xian Deng, John J. Tesmer, Tien-Yi Lee, Young Min Kwon, Daquan Gao
-
Patent number: 9200265Abstract: Embodiments of the invention disclosed herein generally relate to anti-cocaine therapeutics. Specifically, some embodiments of the invention relate to highly efficient, thermostable, and long-lasting cocaine esterase (CocE) mutants that can protect against the toxic and reinforcing effects of cocaine in subjects. Provided herein are mutant CocE polypeptides displaying thermostable esterase activity. Also provided are methods of treating cocaine-induced conditions in a subject in need via administration of mutant CocE as well as methods for high-throughput screening of candidate esterase polypeptides.Type: GrantFiled: November 14, 2012Date of Patent: December 1, 2015Assignees: The Trustees of Columbia University in the City of New York, The Regents of the University of Michigan, University of Kentucky Research FoundationInventors: Donald Landry, Chang-Guo Zhan, James H. Woods, Roger Sunahara, Diwahar L. Narasimhan, Joanne MacDonald, Victor Yang, Mei-Chuan Holden Ko, Shi-Xian Deng, John J. Tesmer, Tien-Yi Lee, Young Min Kwon, Daquan Gao
-
Publication number: 20100034799Abstract: Embodiments of the invention disclosed herein generally relate to anti-cocaine therapeutics. Specifically, some embodiments of the invention relate to highly efficient, thermostable, and long-lasting cocaine esterase (CocE) mutants that can protect against the toxic and reinforcing effects of cocaine in subjects. Provided herein are mutant CocE polypeptides displaying thermostable esterase activity. Also provided are methods of treating cocaine-induced conditions in a subject in need via administration of mutant CocE as well as methods for high-throughput screening of candidate esterase polypeptides.Type: ApplicationFiled: July 10, 2007Publication date: February 11, 2010Inventors: Donald Landry, Chang-Guo Zhan, James H. Woods, Roger Sunahara, Diwahar L. Narasimhan, Joanne MacDonald, Victor Yang, Mei-Chuan Holden Ko, Shi-Xian Deng, John J. Tesmer, Tien-Yi Lee, Young Min Kwon, Daquan Gao
-
Patent number: 7432242Abstract: The present invention relates to novel inhibitors of G-protein signaling. In particular, the present invention provides peptide inhibitors of G protein signaling proteins and methods of using such inhibitors to modulate physiological effects of G protein signaling. The present invention thus provides novel drug targets for a variety of pathologies mediated by defects in G-protein signaling.Type: GrantFiled: February 13, 2003Date of Patent: October 7, 2008Assignee: The Regents of the University of MichiganInventors: Henry I. Mosberg, Richard R. Neubig, Yafei Jin, Hauiling Zhong, Roger Sunahara
-
Publication number: 20040053821Abstract: The present invention relates to novel inhibitors of G-protein signaling. In particular, the present invention provides peptide inhibitors of G protein signaling proteins and methods of using such inhibitors to modulate physiological effects of G protein signaling. The present invention thus provides novel drug targets for a variety of pathologies mediated by defects in G-protein signaling.Type: ApplicationFiled: February 13, 2003Publication date: March 18, 2004Applicant: The Regents of the University of MichiganInventors: Henry I. Mosberg, Richard R. Neubig, Yafei Jin, Hauiling Zhong, Roger Sunahara